A Randomized, Double-blind, Two Treatment, Two Period, Chronic dosing (4 weeks), Crossover, Multi-center Pilot study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycopyrronium/Formoterol Fumarate on Specific Image based Airway Volumes and Resistance in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
Most Recent Events
- 21 Oct 2020 Primary endpoint (Change in corrected airway resistance measured by functional respiratory measured by funtional respiratory imaging) has been met as per results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 21 Oct 2020 Primary endpoint (Change in corrected airway volume as measured by funtional respiratory imaging) has been met as per results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 21 Oct 2020 Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians